Publicacions (31) Publicacions de LUCIA GONZALEZ CORTIJO

2024

  1. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

2023

  1. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

  2. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

  3. Targeting carcinoma-associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis

    Journal of Pathology, Vol. 261, Núm. 2, pp. 238-251

  4. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement

    eClinicalMedicine, Vol. 60

2022

  1. Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer

    Frontiers in Oncology, Vol. 12

  2. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

  3. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

    European Journal of Cancer, Vol. 161, pp. 26-37

2021

  1. MRI guided ROLL/SNOLL in breast cancer patients treated with neoadjuvant chemotherapy

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 40, Núm. 2, pp. 91-99

  2. Mesothelial‐to‐mesenchymal transition and exosomes in peritoneal metastasis of ovarian cancer

    International Journal of Molecular Sciences, Vol. 22, Núm. 21

  3. Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy

    Annals of Oncology

2020

  1. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)

    EClinicalMedicine, Vol. 28

  2. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

  3. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  4. Patterns of relapse and pathological response according to surrogate type in breast cancer patients treated with neoadjuvant chemotherapy and negative axillary involvement

    Clinica e Investigacion en Ginecologia y Obstetricia, Vol. 48, Núm. 4

  5. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2019

  1. Nintedanib plus letrozole in early breast cancer: A phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

    Breast Cancer Research, Vol. 21, Núm. 1

  2. Prognosis and treatment-selection criteria for patients with high-grade stage IIIc-IV serous ovarian, fallopian tube or peritoneal cancer

    Progresos de Obstetricia y Ginecologia, Vol. 62, Núm. 2, pp. 130-135

2018

  1. Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers

    Annals of Oncology, Vol. 29, pp. ix24

2015

  1. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137